Published in Neuropeptides on May 30, 1986
Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A (1989) 2.51
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol (2000) 1.25
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br J Pharmacol (1999) 0.91
The contributions of mu-, delta- and kappa-opioid receptors to the actions of endogenous opioids on spinal reflexes in the rabbit. Br J Pharmacol (1987) 0.90
Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor. Neuropharmacology (2017) 0.75
Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc Natl Acad Sci U S A (1973) 3.91
Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol (1995) 3.44
The relation between intercellular coupling and electrical noise in turtle photoreceptors. J Physiol (1976) 2.76
Colour-dependence of cone responses in the turtle retina. J Physiol (1973) 2.71
High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol (2000) 2.51
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Analysis of electrical noise in turtle cones. J Physiol (1977) 2.38
Two types of luminosity horizontal cells in the retina of the turtle. J Physiol (1973) 2.31
Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur J Pharmacol (1981) 2.14
Spontaneous voltage fluctuations in retinal cones and bipolar cells. Nature (1975) 2.05
Further properties of stereospecific opiate binding sites in rat brain: on the nature of the sodium effect. J Pharmacol Exp Ther (1975) 1.68
Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature (1976) 1.52
Altered stationary-phase response in a Borrelia burgdorferi rpoS mutant. J Bacteriol (2000) 1.49
Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol (1999) 1.48
The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci (2003) 1.47
Fast-track cardiac anesthesia in patients with sickle cell abnormalities. Anesth Analg (1999) 1.46
Interactions leading to horizontal cell responses in the turtle retina. J Physiol (1974) 1.41
Distribution of stereospecific binding of the potent narcotic analgesic etorphine in the human brain: predominance in the limbic system. Res Commun Chem Pathol Pharmacol (1973) 1.36
Surface exposure and protease insensitivity of Borrelia burgdorferi Erp (OspEF-related) lipoproteins. Microbiology (2001) 1.35
Isolation and partial characterization of Borrelia burgdorferi inner and outer membranes by using isopycnic centrifugation. J Bacteriol (1994) 1.35
Polyamines and inhibition of RNA synthesis in E. coli by levorphanol. Biochem Biophys Res Commun (1966) 1.34
Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci (1983) 1.30
Studies on the intracellular distribution and tissue binding of dihydromorphine-7,8-H3 in the rat. Proc Soc Exp Biol Med (1966) 1.30
Coupling of a new, active morphine derivative to sepharose for affinity chromatography. Proc Natl Acad Sci U S A (1972) 1.29
Effects of levorphanol on phospholipid metabolism and composition in Escherichia coli. Biochim Biophys Acta (1971) 1.28
Effects of local anaesthetics on phospholipases. Biochim Biophys Acta (1976) 1.27
Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther (1998) 1.24
Distinct regulatory pathways control expression of Borrelia burgdorferi infection-associated OspC and Erp surface proteins. Infect Immun (2001) 1.21
POLTERGEIST functions to regulate meristem development downstream of the CLAVATA loci. Development (2000) 1.21
Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther (1998) 1.19
The radioimmunoassay of buprenorphine. Eur J Clin Pharmacol (1980) 1.17
Properties of centre-hyperpolarizing, red-sensitive bipolar cells in the turtle retina. J Physiol (1975) 1.16
Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem (1982) 1.16
Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res (2001) 1.15
Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. J Pharmacol Exp Ther (2000) 1.14
Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther (1997) 1.12
Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions. Proc Natl Acad Sci U S A (1975) 1.11
Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs. Eur J Pharmacol (1977) 1.10
The effects of the morphine analogue levorphanol on leukocytes. Metabolic effects at rest and during phagocytosis. J Clin Invest (1971) 1.10
A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience (2007) 1.08
Solubilization of a stereospecific opiate-macromolecular complex from rat brain. Science (1975) 1.08
Specific, high affinity [3H]ethylketocyclazocine binding in rat central nervous system: lack of evidence for kappa receptors. J Pharmacol Exp Ther (1980) 1.07
3H-ethylketocyclazocine binding: lack of evidence for a separate kappa receptor in rats CNS. Eur J Pharmacol (1979) 1.07
Biochemical analysis of the arginine methylation of high molecular weight fibroblast growth factor-2. J Biol Chem (2000) 1.07
Effect of levorphanol on putrescine transport in Escherichia coli. Mol Pharmacol (1970) 1.04
Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors. Proc Natl Acad Sci U S A (1980) 1.04
The use of [3H]-[D-Pen2,D-Pen5]enkephalin as a highly selective ligand for the delta-binding site. Br J Pharmacol (1985) 1.03
Electrical responses of double cones in the turtle retina. J Physiol (1974) 1.03
On the mechanisms of kappa-opioid-induced diuresis. Br J Pharmacol (1986) 1.01
Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor. Br J Pharmacol (2009) 0.99
Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs. Br J Clin Pharmacol (1979) 0.99
Comparative studies on synaptosomes: uptake of (N-Me-3H)choline by synaptosomes from squid optic lobes. J Neurochem (1973) 0.99
Supplemental vitamin C and yeast cell wall beta-glucan as growth enhancers in newborn pigs and as immunomodulators after an endotoxin challenge after weaning. J Anim Sci (2006) 0.98
Opiate receptors in the rat vas deferens. Life Sci (1983) 0.98
ICI 204448: a kappa-opioid agonist with limited access to the CNS. Br J Pharmacol (1989) 0.97
Solubilization of an active opiate receptor from Bufo marinus. Eur J Pharmacol (1980) 0.97
A novel series of potent and selective agonists at the opioid kappa-receptor. Eur J Pharmacol (1988) 0.97
Purification of an active opioid-binding protein from bovine striatum. J Biol Chem (1985) 0.97
GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther (2001) 0.96
Covalent labeling of opioid receptors with radioiodinated human beta-endorphin. Identification of binding site subunit. J Biol Chem (1985) 0.96
Mu-receptor binding in physiological media: comparison with isolated tissue data. Neuropeptides (1984) 0.96
Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: II. Activation and involvement of the alpha, epsilon, and zeta isoforms of PKC. J Neurochem (1999) 0.95
mu and delta-opioid receptor agonists induce mitogen-activated protein kinase (MAPK) activation in the absence of receptor internalization. Neuropharmacology (2000) 0.95
Multiple opiate binding sites in rat spinal cord. Life Sci (1983) 0.94
Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model. Mol Pharmacol (2008) 0.94
Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther (2003) 0.94
Opiate receptors and their interactions with agnoists and antagonists. Life Sci (1975) 0.93
Characterization of ZFOR1, a putative delta-opioid receptor from the teleost zebrafish (Danio rerio). Neurosci Lett (2000) 0.93
Effects of antimalarial drugs on phospholipase A2 [proceedings]. Br J Pharmacol (1979) 0.93
A simultaneous determination of acetylsalicylic acid, salicylic acid and salicylamide in plasma by gas liquid chromatography. J Pharm Pharmacol (1975) 0.92
Effects of dietary arginine supplementation during gestation and lactation on the performance of lactating primiparous sows and nursing piglets. J Anim Sci (2007) 0.92
Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays. Eur J Pharmacol (1999) 0.92
Solubilization and characterization of active opiate binding sites from mammalian brain. J Pharmacol Exp Ther (1982) 0.92
Effect of glutamine and spray-dried plasma on growth performance, small intestinal morphology, and immune responses of Escherichia coli K88+-challenged weaned pigs. J Anim Sci (2005) 0.92
Subcellular localisation of leucine-enkephalin-hydrolysing activity in rat brain. Nature (1977) 0.91
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br J Pharmacol (1999) 0.91
Tyrosine phosphorylation of the delta-opioid receptor. Evidence for its role in mitogen-activated protein kinase activation and receptor internalization*. Biochem Pharmacol (2000) 0.91
The effects of thermal environment and spray-dried plasma on the acute-phase response of pigs challenged with lipopolysaccharide. J Anim Sci (2003) 0.91
Ontological development of opiate receptors in rodent brain. Brain Res (1976) 0.90
A luminescent ruthenium complex for ultrasensitive detection of proteins immobilized on membrane supports. Anal Biochem (1999) 0.90
Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein. J Pharmacol Exp Ther (2001) 0.90
Evaluation of physiological and blood serum differences in heat-tolerant (Romosinuano) and heat-susceptible (Angus) Bos taurus cattle during controlled heat challenge. J Anim Sci (2010) 0.90
Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol (2014) 0.90
Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors. J Pept Res (2005) 0.90
Solubilization and characterization of mu, delta, and kappa opioid binding sites from guinea pig brain: physical separation of kappa receptors. Proc Natl Acad Sci U S A (1984) 0.90
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem (2009) 0.90
The action of various venoms on Escherichia coli. J Appl Bacteriol (1986) 0.90
[3H]diprenorphine binding to kappa-sites in guinea-pig and rat brain: evidence for apparent heterogeneity. J Neurochem (1989) 0.90
Multiple opiate receptors: alcohol selectively inhibits binding to delta receptors. Science (1981) 0.89
Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J Med Chem (1995) 0.89
Metabolism of polyamines in mouse neuroblastoma cells in culture: formation of GABA and putreanine. J Neurochem (1975) 0.89
Characterisation of kappa-opioid binding sites in rat and guinea-pig spinal cord. Neuropharmacology (1989) 0.88
Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues. J Med Chem (2000) 0.88
Phospholipase A2 activity of lysosomal origin secreted by polymorphonuclear leucocytes during phagocytosis or on treatment with calcium. Biochim Biophys Acta (1981) 0.88
Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth (1993) 0.87
Identification of a neurorestrictive suppressor element (NRSE) in the human mu-opioid receptor gene. Brain Res Mol Brain Res (2001) 0.87
The opiate receptors. Annu Rev Pharmacol Toxicol (1978) 0.87
Evidence for the presence of disulfide bridges in opioid receptors essential for ligand binding. Possible role in receptor activation. J Mol Recognit (1989) 0.87